Stability Indicating Analytical Method Development and Validation for the Simultaneous Determination of Degradation Impurities of Buprenorphine and Naloxone in Combination Pharmaceutical Dosage Form by RP-HPLC — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Stability Indicating Analytical Method Development and Validation for the Simultaneous Determination of Degradation Impurities of Buprenorphine and Naloxone in Combination Pharmaceutical Dosage Form by RP-HPLC
Ascent Pharmaceuticals, Inc., 400 S. Technology Drive, Central Islip, New York, USA
,
Ascent Pharmaceuticals, Inc., 400 S. Technology Drive, Central Islip, New York, USA
1 Ascent Pharmaceuticals, Inc., 400 S. Technology Drive, Central Islip, New York, USA
2 Ascent Pharmaceuticals, Inc., 400 S. Technology Drive, Central Islip, New York, USA
A stability-indicating reverse-phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for the simultaneous quantitative determination of degradation products of Buprenorphine and Naloxone in a combination pharmaceutical dosage form. Efficient chromatographic separation was achieved using gradient elution with mixture of acetonitrile and 50 mM potassium phosphate monobasic buffer (adjusted to pH 4.5 with diluted phosphoric acid) as mobile phase A, and acetonitrile as mobile phase B. The separation was performed on a Phenomenex Luna C18 column (4.6 × 100 mm, 3 µm). UV detection was carried out at 280 nm, with flow rates of 1.1 mL/min and 1.2 mL/min. The method was validated in accordance with ICH guidelines to demonstrate specificity, linearity, limits of detection and quantitation, precision, accuracy, robustness, and solution stability. This validated method was successfully applied for the simultaneous quantitative determination of degradation products of Buprenorphine and Naloxone in the combination dosage form during both release testing and shelf-life stability studies.
United States Pharmacopeia (USP/NF) (2022) United States Pharmacopeia Monogrpah (USP) for Buprenorphine Hydrochloride. https://doi.org/10.31003/USPNF_M10510_06_01
Tzschentke, T.M. (2002) Behavioral Pharmacology of Buprenorphine, with a Focus on Preclinical Models of Reward and Addiction. Psychopharmacology , 161, 1-16. https://doi.org/10.1007/s00213-002-1003-8
Davis, M.P. (2005) Buprenorphine in Cancer Pain. Supportive Care in Cancer , 13, 878-887. https://doi.org/10.1007/s00520-005-0849-9
Shulman, M., Wai, J.M. and Nunes, E.V. (2019) Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs , 33, 567-580. https://doi.org/10.1007/s40263-019-00637-z
United States Pharmacopeia (USP/NF) (2022) United States Pharmacopeia Monogrpah (USP) for Buprenorphine Hydrochloride. https://doi.org/10.31003/USPNF_M10510_06_01
Hoskin, P.J. and Hanks, G.W. (1991) Opioid Agonist-Antagonist Drugs in Acute and Chronic Pain States. Drugs , 41, 326-344. https://doi.org/10.2165/00003495-199141030-00002
Michaelis, L.L., Hickey, P.R., Clark, T.A. and Dixon, W.M. (1974) Ventricular Irritability Associated with the Use of Naloxone Hydrochloride: Two Case Reports and Laboratory Assessment of the Effect of the Drug on Cardiac Excitability. The Annals of Thoracic Surgery , 18, 608-614. https://doi.org/10.1016/s0003-4975(10)64408-6
Lutfy, K. and Cowan, A. (2004) Buprenorphine: A Unique Drug with Complex Pharmacology. Current Neuropharmacology , 2, 395-402. https://doi.org/10.2174/157015904335947
Collins, G.B. and McAllister, M.S. (2007) Buprenorphine Maintenance: A New Treatment for Opioid Dependence. Cleveland Clinic Journal of Medicine , 74, 514-520. https://doi.org/10.3949/ccjm.74.7.514
Bell, J., Shanahan, M., Mutch, C., Rea, F., Ryan, A., Batey, R., et al . (2007) A Randomized Trial of Effectiveness and Cost-Effectiveness of Observed versus Unobserved Administration of Buprenorphine-Naloxone for Heroin Dependence. Addiction , 102, 1899-1907. https://doi.org/10.1111/j.1360-0443.2007.01979.x
Mostafavi, A., Abedi, G., Jamshidi, A., Afzali, D. and Talebi, M. (2009) Development and Validation of a HPLC Method for the Determination of Buprenorphine Hydrochloride, Naloxone Hydrochloride and Noroxymorphone in a Tablet Formulation. Talanta , 77, 1415-1419. https://doi.org/10.1016/j.talanta.2008.09.024
Liu, S.Y., Liu, K.S., Kuei, C.H., Tzeng, J.I., et al . (2005) Simultaneous Determination of Buprenorphine and Its Prodrug, Buprenorphine Propionate, by High-Performance Liquid Chromatography with Fluorescence Detection. Journal of Chromatography B , 818, 233-239. https://doi.org/10.1016/j.jchromb.2005.01.002
Pirnay, S., Hervé, F., Bouchonnet, S., Perrin, B., Baud, F.J. and Ricordel, I. (2006) Liquid Chromatographic–Electrospray Ionization Mass Spectrometric Quantitative Analysis of Buprenorphine, Norbuprenorphine, Nordiazepam and Oxazepam in Rat Plasma. Journal of Pharmaceutical and Biomedical Analysis , 41, 1135-1145. https://doi.org/10.1016/j.jpba.2006.02.020
Rodriguez-Rosas, M.E., Lofwall, M.R., Strain, E.C., Siluk, D. and Wainer, I.W. (2007) Simultaneous Determination of Buprenorphine, Norbuprenorphine and the Enantiomers of Methadone and Its Metabolite (EDDP) in Human Plasma by Liquid Chromatography/Mass Spectrometry. Journal of Chromatography B , 850, 538-543. https://doi.org/10.1016/j.jchromb.2006.11.025
Damodar, K. (2011) Analytical Method Development and Validation for the Simultaneous Estimation of Buprenorphine Hydrochloride and Naloxone Hydrochloride in Pharmaceutical Dosage Forms by RPHPLC. International Journal of Pharmaceutical and Biological Archive , 2, 1751-1756.
Mundhey, D.A., Sapkal, N.P. and Daud, A.S. (2016) Simultaneous Quantification of Buprenorphine HCl and Naloxonehcl by Vierordt’s Method. International Journal of Pharmacy and Pharmaceutical Science , 8, 101-107.
International Council for Harmonization (ICH): Validation of Analytical Procedures Q2(R2).
Reynolds, D.W., Facchine, K.L., Mullaney, J.F., Alsante, K.M., Hatajik, T.D. and Motto, M.G. (2002) Available Guidance and Best Practices for Conducting Forced Degradation Studies. Pharmacy Technician , 26, 48-56.
Alsante, K.M., Ando, A., Brown, R., Ensing, J., Hatajik, T.D., Kong, W. and Tsuda, Y. (2007) The Role of Degradant Profiling in Active Pharmaceutical Ingredients and Drug Products. Advanced Drug Delivery Reviews , 59, 29-37. https://doi.org/10.1016/j.addr.2006.10.006
Ruan, J., Tattersall, P., Lozano, R. and Shah, P. (2009) The Role of Forced Degradation Studies in Stability Indicating HPLC Method Development. American Pharmaceutical Review , 9, 46-53.
O’Neill, R., Yoo, O., Burcham, P., Nguyen, M. and Lim, L.Y. (2025) Development and Validation of a Stability-Indicating RP-HPLC Method for Edaravone Quantification. Molecules , 30, Article 2866. https://doi.org/10.3390/molecules30132866
Zhang, L.X., Li, X.Y., Zhang, J.S., et al . (2025) A Validated, Stability‐indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance. Biomedical Chromatography , 39, e70118. https://doi.org/10.1002/bmc.70118
Marie, A.A., Yassin, M.G. and Elshenawy, E.A. (2025) Stability Indicating RP-HPLC Method for Estimation of Finerenone and Its Related Substances in New Dosage Form. Scientific Reports , 15, Article No. 20229. https://doi.org/10.1038/s41598-025-07166-4